Antigen-presenting cell engineering. The molecular toolbox.
作者信息
Tykocinski M L, Kaplan D R, Medof M E
机构信息
Department of Pathology, Case Western Reserve University, Cleveland, Ohio 44106, USA.
出版信息
Am J Pathol. 1996 Jan;148(1):1-16.
Abstract
摘要
相似文献
1
Antigen-presenting cell engineering. The molecular toolbox.
Am J Pathol. 1996 Jan;148(1):1-16.
2
Tumour immunotherapy: the adjuvant treatment of the 21st century?
Eur J Surg Oncol. 2000 Jun;26(4):418-24. doi: 10.1053/ejso.1999.0908.
3
Quality and quantity: new strategies to improve immunotherapy of cancer.
Trends Mol Med. 2004 May;10(5):205-8. doi: 10.1016/j.molmed.2004.03.004.
4
Genetically engineered fibroblasts with antigen-presenting capability: efficient induction of an antigen-specific cytotoxic T-lymphocyte response and protection against tumor development in vivo.
Cancer Gene Ther. 2000 Jun;7(6):861-9. doi: 10.1038/sj.cgt.7700193.
5
On immunotherapies and cancer vaccination protocols: a mathematical modelling approach.
J Theor Biol. 2009 Aug 21;259(4):820-7. doi: 10.1016/j.jtbi.2009.05.001. Epub 2009 May 14.
6
Nonreplicating recombinant vaccinia virus expressing CD40 ligand enhances APC capacity to stimulate specific CD4+ and CD8+ T cell responses.
Hum Gene Ther. 2005 Mar;16(3):348-60. doi: 10.1089/hum.2005.16.348.
7
Spinning molecular immunology into successful immunotherapy.
Nat Rev Immunol. 2002 Apr;2(4):227-38. doi: 10.1038/nri774.
8
[Cellular immunotherapy with genetically engineered T-cell therapy for malignancies].
Rinsho Ketsueki. 2011 May;52(5):243-55.
9
Recognition of tumor glycans by antigen-presenting cells.
Curr Opin Immunol. 2006 Feb;18(1):105-11. doi: 10.1016/j.coi.2005.11.001. Epub 2005 Nov 21.
10
Paracrine cytokine adjuvants in cancer immunotherapy.
Annu Rev Immunol. 1995;13:399-415. doi: 10.1146/annurev.iy.13.040195.002151.
引用本文的文献
1
(Patho)Physiology of Glycosylphosphatidylinositol-Anchored Proteins II: Intercellular Transfer of Matter (Inheritance?) That Matters.
Biomolecules. 2023 Jun 15;13(6):994. doi: 10.3390/biom13060994.
2
Targeting the B7 family of co-stimulatory molecules: successes and challenges.
BioDrugs. 2013 Feb;27(1):1-13. doi: 10.1007/s40259-012-0001-6.
3
Killer artificial antigen-presenting cells: the synthetic embodiment of a 'guided missile'.
Immunotherapy. 2010 Jul;2(4):539-50. doi: 10.2217/imt.10.26.
4
New designs for cancer vaccine and artificial veto cells: an emerging palette of protein paints.
Immunol Res. 2003;27(2-3):565-74. doi: 10.1385/IR:27:2-3:565.
5
6
Molecular analysis of premalignant and carcinoma in situ lesions of the human breast.
Am J Pathol. 1996 Sep;149(3):733-8.
本文引用的文献
1
Mature T cells of autoimmune lpr/lpr mice have a defect in antigen-stimulated suicide.
Proc Natl Acad Sci U S A. 1993 May 15;90(10):4409-13. doi: 10.1073/pnas.90.10.4409.
2
Prospects for anti-rejection therapies based upon CD8-dependent immunoregulation.
Kidney Int Suppl. 1993 Jan;39:S120-3.
3
The use of palmitate-conjugated protein A for coating cells with artificial receptors which facilitate intercellular interactions.
J Immunol Methods. 1993 Jan 14;158(1):57-65. doi: 10.1016/0022-1759(93)90258-9.
4
Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor I RNA.
Science. 1993 Jan 1;259(5091):94-7. doi: 10.1126/science.8418502.
5
Peripheral T cell activation and deletion induced by transfer of lymphocyte subsets expressing endogenous or exogenous mouse mammary tumor virus.
J Exp Med. 1993 May 1;177(5):1359-66. doi: 10.1084/jem.177.5.1359.
6
Genetically engineered vaccines. Comparison of active versus passive immunotherapy against solid tumors.
Ann N Y Acad Sci. 1993 Aug 12;690:244-55. doi: 10.1111/j.1749-6632.1993.tb44013.x.
7
The structure and biosynthesis of glycosyl phosphatidylinositol protein anchors.
Annu Rev Biochem. 1993;62:121-38. doi: 10.1146/annurev.bi.62.070193.001005.
8
Cognate peptide-induced destruction of CD8+ cytotoxic T lymphocytes is due to fratricide.
J Immunol. 1993 Jul 15;151(2):658-67.
9
Tumor cells transfected with a bacterial heat-shock gene lose tumorigenicity and induce protection against tumors.
J Exp Med. 1993 Jul 1;178(1):343-8. doi: 10.1084/jem.178.1.343.
10
Levels of peripheral T cell tolerance induced by different doses of tolerogen.
Science. 1994 Feb 4;263(5147):674-6. doi: 10.1126/science.8303275.
Zotero 插件